Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin

Nandigama Krishnamachary, Liangdong Ma, Ling Zheng, Ahmad Safa, Melvin S. Center

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

In an effort to define clearly the basis of non-P-glycoprotein multidrug resistance in HL60/ADR cells, we have analyzed expression of MRP mRNA levels and the MRP-encoded protein in resistant cells and also in resistant cells that have undergone a reversion to drug sensitivity. The results demonstrate that an MRP cDNA containing 5′-end coding sequences reacts with a 6-kb RNA, which is overexpressed in the resistant isolate. As resistant cells revert to drug sensitivity there is essentially a complete loss of the 6-kb RNA. Southern blot analysis indicates that the MRP gene is amplified compared to the copy number found in sensitive cells. Revertant cells no longer contain amplified MRP sequences. Western blot analysis has been conducted using an antibody prepared against the carboxyl terminus (15 amino acids) of the deduced sequence of the MRP-encoded protein. The antibody is reactive with a 190-kDa protein (P190) and with two closely migrating proteins of 65 and 70 kDa (P70), which are overexpressed in plasma membranes and endoplasmic reticulum of resistant cells. Both proteins are greatly reduced in revertant cells. Growth of cells in the presence of tunicamycin demonstrates that both P190 and P70 are glycosylated, with the deglycosylated forms migrating in polyacrylamide gels as proteins of 165 kDa and 45 kDa, respectively. Additional antisera have also been prepared against sequence domains contained in the C-terminal region of P190. These antisera are reactive with both P190 and P70. Antisera directed against sequences of the amino terminal region of P190 do not react with P70. The C-terminal region of P190 seems to have a major sequence homology with P70, and P70 seems to represent a selective cleavage product formed from the carboxyl terminus of P190. Previous studies have shown that HL60/ADR cells are defective in drug accumulation. This function is greatly reduced in cells which have reverted to drug sensitivity. The results of these studies therefore provide evidence that the MRP gene contributes to resistance of HL60/ADR and that the protein encoded by this gene can function to reduce drug accumulation.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalOncology Research
Volume6
Issue number3
StatePublished - 1994
Externally publishedYes

Fingerprint

HL-60 Cells
Doxorubicin
Gene Expression
Proteins
Immune Sera
Pharmaceutical Preparations
RNA
Tunicamycin
Antibodies
Multiple Drug Resistance
Sequence Homology
Southern Blotting
Endoplasmic Reticulum
Genes
Amino Acid Sequence
Glycoproteins
Complementary DNA
Western Blotting
Cell Membrane
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research

Cite this

Krishnamachary, N., Ma, L., Zheng, L., Safa, A., & Center, M. S. (1994). Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncology Research, 6(3), 119-127.

Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. / Krishnamachary, Nandigama; Ma, Liangdong; Zheng, Ling; Safa, Ahmad; Center, Melvin S.

In: Oncology Research, Vol. 6, No. 3, 1994, p. 119-127.

Research output: Contribution to journalArticle

Krishnamachary, N, Ma, L, Zheng, L, Safa, A & Center, MS 1994, 'Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin', Oncology Research, vol. 6, no. 3, pp. 119-127.
Krishnamachary, Nandigama ; Ma, Liangdong ; Zheng, Ling ; Safa, Ahmad ; Center, Melvin S. / Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. In: Oncology Research. 1994 ; Vol. 6, No. 3. pp. 119-127.
@article{6626e9bad9894d66bd59316e76d12821,
title = "Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin",
abstract = "In an effort to define clearly the basis of non-P-glycoprotein multidrug resistance in HL60/ADR cells, we have analyzed expression of MRP mRNA levels and the MRP-encoded protein in resistant cells and also in resistant cells that have undergone a reversion to drug sensitivity. The results demonstrate that an MRP cDNA containing 5′-end coding sequences reacts with a 6-kb RNA, which is overexpressed in the resistant isolate. As resistant cells revert to drug sensitivity there is essentially a complete loss of the 6-kb RNA. Southern blot analysis indicates that the MRP gene is amplified compared to the copy number found in sensitive cells. Revertant cells no longer contain amplified MRP sequences. Western blot analysis has been conducted using an antibody prepared against the carboxyl terminus (15 amino acids) of the deduced sequence of the MRP-encoded protein. The antibody is reactive with a 190-kDa protein (P190) and with two closely migrating proteins of 65 and 70 kDa (P70), which are overexpressed in plasma membranes and endoplasmic reticulum of resistant cells. Both proteins are greatly reduced in revertant cells. Growth of cells in the presence of tunicamycin demonstrates that both P190 and P70 are glycosylated, with the deglycosylated forms migrating in polyacrylamide gels as proteins of 165 kDa and 45 kDa, respectively. Additional antisera have also been prepared against sequence domains contained in the C-terminal region of P190. These antisera are reactive with both P190 and P70. Antisera directed against sequences of the amino terminal region of P190 do not react with P70. The C-terminal region of P190 seems to have a major sequence homology with P70, and P70 seems to represent a selective cleavage product formed from the carboxyl terminus of P190. Previous studies have shown that HL60/ADR cells are defective in drug accumulation. This function is greatly reduced in cells which have reverted to drug sensitivity. The results of these studies therefore provide evidence that the MRP gene contributes to resistance of HL60/ADR and that the protein encoded by this gene can function to reduce drug accumulation.",
author = "Nandigama Krishnamachary and Liangdong Ma and Ling Zheng and Ahmad Safa and Center, {Melvin S.}",
year = "1994",
language = "English (US)",
volume = "6",
pages = "119--127",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "3",

}

TY - JOUR

T1 - Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin

AU - Krishnamachary, Nandigama

AU - Ma, Liangdong

AU - Zheng, Ling

AU - Safa, Ahmad

AU - Center, Melvin S.

PY - 1994

Y1 - 1994

N2 - In an effort to define clearly the basis of non-P-glycoprotein multidrug resistance in HL60/ADR cells, we have analyzed expression of MRP mRNA levels and the MRP-encoded protein in resistant cells and also in resistant cells that have undergone a reversion to drug sensitivity. The results demonstrate that an MRP cDNA containing 5′-end coding sequences reacts with a 6-kb RNA, which is overexpressed in the resistant isolate. As resistant cells revert to drug sensitivity there is essentially a complete loss of the 6-kb RNA. Southern blot analysis indicates that the MRP gene is amplified compared to the copy number found in sensitive cells. Revertant cells no longer contain amplified MRP sequences. Western blot analysis has been conducted using an antibody prepared against the carboxyl terminus (15 amino acids) of the deduced sequence of the MRP-encoded protein. The antibody is reactive with a 190-kDa protein (P190) and with two closely migrating proteins of 65 and 70 kDa (P70), which are overexpressed in plasma membranes and endoplasmic reticulum of resistant cells. Both proteins are greatly reduced in revertant cells. Growth of cells in the presence of tunicamycin demonstrates that both P190 and P70 are glycosylated, with the deglycosylated forms migrating in polyacrylamide gels as proteins of 165 kDa and 45 kDa, respectively. Additional antisera have also been prepared against sequence domains contained in the C-terminal region of P190. These antisera are reactive with both P190 and P70. Antisera directed against sequences of the amino terminal region of P190 do not react with P70. The C-terminal region of P190 seems to have a major sequence homology with P70, and P70 seems to represent a selective cleavage product formed from the carboxyl terminus of P190. Previous studies have shown that HL60/ADR cells are defective in drug accumulation. This function is greatly reduced in cells which have reverted to drug sensitivity. The results of these studies therefore provide evidence that the MRP gene contributes to resistance of HL60/ADR and that the protein encoded by this gene can function to reduce drug accumulation.

AB - In an effort to define clearly the basis of non-P-glycoprotein multidrug resistance in HL60/ADR cells, we have analyzed expression of MRP mRNA levels and the MRP-encoded protein in resistant cells and also in resistant cells that have undergone a reversion to drug sensitivity. The results demonstrate that an MRP cDNA containing 5′-end coding sequences reacts with a 6-kb RNA, which is overexpressed in the resistant isolate. As resistant cells revert to drug sensitivity there is essentially a complete loss of the 6-kb RNA. Southern blot analysis indicates that the MRP gene is amplified compared to the copy number found in sensitive cells. Revertant cells no longer contain amplified MRP sequences. Western blot analysis has been conducted using an antibody prepared against the carboxyl terminus (15 amino acids) of the deduced sequence of the MRP-encoded protein. The antibody is reactive with a 190-kDa protein (P190) and with two closely migrating proteins of 65 and 70 kDa (P70), which are overexpressed in plasma membranes and endoplasmic reticulum of resistant cells. Both proteins are greatly reduced in revertant cells. Growth of cells in the presence of tunicamycin demonstrates that both P190 and P70 are glycosylated, with the deglycosylated forms migrating in polyacrylamide gels as proteins of 165 kDa and 45 kDa, respectively. Additional antisera have also been prepared against sequence domains contained in the C-terminal region of P190. These antisera are reactive with both P190 and P70. Antisera directed against sequences of the amino terminal region of P190 do not react with P70. The C-terminal region of P190 seems to have a major sequence homology with P70, and P70 seems to represent a selective cleavage product formed from the carboxyl terminus of P190. Previous studies have shown that HL60/ADR cells are defective in drug accumulation. This function is greatly reduced in cells which have reverted to drug sensitivity. The results of these studies therefore provide evidence that the MRP gene contributes to resistance of HL60/ADR and that the protein encoded by this gene can function to reduce drug accumulation.

UR - http://www.scopus.com/inward/record.url?scp=0028016044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028016044&partnerID=8YFLogxK

M3 - Article

C2 - 7994083

AN - SCOPUS:0028016044

VL - 6

SP - 119

EP - 127

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 3

ER -